

Adeno-associated Virus Serotype rh74 Prevalence in Muscular Dystrophy Population

#724

Danielle A. Griffin^{1,3}, Rachael A. Potter^{1,3}, Eric R. Pozsgai^{1,3}, Ellyn L. Peterson^{1,3} and Louise R. Rodino-Klapac^{1,2,3}

¹Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA, ²Department of Pediatrics and Neurology, The Ohio State University, Columbus, Ohio, USA, ³Sarepta Therapeutics, Cambridge, Massachusetts, USA.

BACKGROUND

- Pre-existing antibodies against adeno-associated virus (AAV) are a major challenge impacting efficacy of *in vivo* gene therapy, as AAV is the most common vehicle used for *in vivo* gene transfer.¹⁻³
- To avoid the potential for blocking of the viral vector, current AAV gene therapy delivery practices require subjects to be free of antibodies against specific AAV serotypes before treatment.
- During candidate selection for our Duchenne muscular dystrophy (DMD) and limb girdle muscular dystrophy (LGMD) type 2E, 2C, 2D, 2B gene therapy clinical trials (NCT03652259, NCT01976091, NCT02710500, NCT03769116), patients are screened for pre-existing antibodies against AAVrh74 using a validated enzyme-linked immunosorbent assay (ELISA).
- Subjects with an endpoint absorbance ratio ≥ 2.00 detected at a serum dilution of $>1:400$ are considered seropositive and therefore do not meet inclusion criteria for our clinical trials.

OBJECTIVE

This report presents our methodology for detection of pre-existing AAVrh74 antibodies and prevalence in the LGMD and DMD populations screened at our site during clinical trial enrollment.

ELISA

PATIENT POPULATION

- A total of 95 DMD and LGMD (26 DMD, 13 LGMD2E, 19 LGMD2D, 34 LGMD2B and 3 LGMD2C) subjects were screened at Nationwide Children's Hospital (Columbus, Ohio) in this study.

SERUM SAMPLE COLLECTION AND SAMPLE PREPARATION

- Informed consent for participation and sample collection was obtained by the Principal Investigator in compliance with 21CFR50 and the International Conference on Harmonisation guidelines before entering the trials and signed by parents and subjects (for ages <17 years).
- Blood was collected in a BD red top clot activator tube. Blood was spun and serum was collected and stored at -80°C until analysis.

AAV PRODUCTION AND PURIFICATION


- AAVrh74 is a clade E serotype that was isolated from lymph nodes of rhesus monkeys and shares 93% amino acid identity to AAV8.^{4,5}
- Recombinant AAVrh74 (rAAVrh74) was made in the GMP production facility at Nationwide Children's Hospital Manufacturing Facility by triple transfection as previously described.^{6,7}
- For these assays, empty rAAVrh74 capsids could be used.

ELISA METHODOLOGY

- An indirect ELISA method was used to detect the presence of anti-AAVrh74 antibodies in serum samples (Figure 1).

ELISA continued

Figure 1. Step-by-step procedure for detection of anti-AAVrh74 in serum samples



ELISA ANALYSIS

- Raw absorbance values from a 450 nm read were exported to an excel file for computation.
- The optical density (OD) values of the duplicate AAV-coated and non-coated (background) wells were used to determine the absorbance ratio, as follows:

$$\text{Absorbance ratio} = \frac{\text{Average OD}_1 - \text{Average OD}_2}{\text{Average OD}_2}$$

OD₁ = optical density of antigen-coated wells
 OD₂ = optical density of non-coated antigen wells

- This calculation was performed for every dilution (1:25-1:3200) and a ratio ≥ 2.00 was considered a positive antibody response.
- The endpoint rAAVrh74 antibody titers were determined by identifying the last serum dilution that yielded a ratio of ≥ 2.00 .

CONCLUSIONS

- A standardized assay developed to screen for AAVrh74 seropositivity was shown to be an essential tool in screening patients for pre-existing antibodies to minimize safety concerns and improve therapeutic efficacy with rAAVrh74-based gene therapies.
- These findings support the selection of rAAVrh74 as a gene therapy vector and indicate promise that rAAVrh74-based gene therapy will not induce significant anti-capsid immune responses in the majority of patients with muscular dystrophies.

ELISA ANALYSIS continued

- A subject with a ratio of <2.00 at the serum dilution of $>1:400$ would meet inclusion criteria.
- Measures were taken to ensure inter-operator reliability and assay reliability. To confirm validity of the assay, several criteria had to be met (Table 1).

Table 1. Assay validity is confirmed based upon several acceptance criteria

Description of Criteria	Value
Absorbance ratio of positive control	≥ 2.00
Absorbance ratio of negative control A	<2.00
Absorbance ratio of negative control B (no primary antibody buffer only wells)	≤ 1.00
Absorbance ratio of non-coated rAAVrh74 wells	≤ 1.00
Difference in absorbance (optical density) values between duplicates	≤ 0.05

IDENTIFICATION OF THE CUTOFF FOR AAVrh74 SEROPOSITIVE SAMPLES

- Based on a previous study⁸ showing that antibody titers at 1:800 promoted loss of transgene expression, the cutoff used to define seropositivity was $>1:400$.

SEROPREVALENCE

- Of the total 95 patients with muscular dystrophies screened as of September 25, 2018, 83% were identified as seronegative for pre-existing antibodies to AAVrh74 and were eligible for enrollment into our DMD or LGMD gene therapy trials.

ACKNOWLEDGEMENTS & DISCLOSURES

No competing financial interests exist for the authors. This study was sponsored by Sarepta Therapeutics, Inc. and Nationwide Children's Hospital. The authors would like to thank Khampaseuth Thapa for her assistance. Editorial support was provided by Health & Wellness Partners, LLC, Upper Saddle River, New Jersey, funded by Sarepta Therapeutics, Inc.



REFERENCES

- Masat E, et al. *Discov Med*. 2013;15(85):379-389.
- Calcedo R, Wilson JM. *Front Immunol*. 2013;4:341.
- Basner-Tschakarjan E, Mingozzi F. *Front Immunol*. 2014;5:350.
- Johnson PR, et al. *J Virol*. 2005;79(2):955-965.
- Gao G, et al. *J Virol*. 2004;78(12):6381-6388.
- Mendell JR, et al. *Hum Gene Ther*. 2019; Mar 6 [Epub ahead of print].
- Pozsgai ER, et al. *Mol Ther*. 2017;25(4):855-869.
- Chicoine LG, et al. *Mol Ther*. 2014;22(2):338-347.

